These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 35329982)

  • 1. New Generation Gepants: Migraine Acute and Preventive Medications.
    Moreno-Ajona D; Villar-Martínez MD; Goadsby PJ
    J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gepants for Acute and Preventive Migraine Treatment: A Narrative Review.
    Rissardo JP; Caprara ALF
    Brain Sci; 2022 Nov; 12(12):. PubMed ID: 36552072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC; Schwedt TJ
    Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?
    Moreno-Ajona D; Pérez-Rodríguez A; Goadsby PJ
    Curr Opin Neurol; 2020 Jun; 33(3):309-315. PubMed ID: 32251023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacotherapeutic management of episodic and chronic migraine with gepants.
    Tajti J; Szok D; Csáti A; Vécsei L
    Expert Opin Pharmacother; 2023 Jun; 24(8):947-958. PubMed ID: 37038933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raynaud's phenomenon associated with calcitonin gene-related peptide receptor antagonists case report.
    Bedrin K; Ailani J; Dougherty C
    Headache; 2022 Nov; 62(10):1419-1423. PubMed ID: 36426766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CGRP receptor antagonists (gepants).
    Younis S; Latysheva NV; Danilov AB; Ashina M
    Handb Clin Neurol; 2024; 199():51-66. PubMed ID: 38307667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Brief Review of Gepants.
    Li D; Abreu J; Tepper SJ
    Curr Pain Headache Rep; 2023 Sep; 27(9):479-488. PubMed ID: 37531032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration's adverse event reporting system databases.
    Liang Q; Liao X; Wu H; Huang Y; Liang T; Li H
    Front Pharmacol; 2024; 15():1431562. PubMed ID: 39144633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gepants for the treatment of migraine.
    Negro A; Martelletti P
    Expert Opin Investig Drugs; 2019 Jun; 28(6):555-567. PubMed ID: 31081399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CGRP and 5-HT
    Moreno-Ajona D; Chan C; Villar-Martínez MD; Goadsby PJ
    Headache; 2019 Jul; 59 Suppl 2():3-19. PubMed ID: 31291016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine.
    Argyriou AA; Mantovani E; Mitsikostas DD; Vikelis M; Tamburin S
    Expert Rev Neurother; 2022 Jun; 22(6):469-488. PubMed ID: 35707907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gepants - a long way to cure: a narrative review.
    Altamura C; Brunelli N; Marcosano M; Fofi L; Vernieri F
    Neurol Sci; 2022 Sep; 43(9):5697-5708. PubMed ID: 35650458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel synthetic treatment options for migraine.
    Negro A; Martelletti P
    Expert Opin Pharmacother; 2021 May; 22(7):907-922. PubMed ID: 33369482
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on gepants for the treatment of chronic migraine.
    Aoh Y; Hou TW; Yang CC; Chang CM; Chen SP; Tsai IJ; Cheng CW; Yang CP
    J Chin Med Assoc; 2024 Apr; 87(4):350-356. PubMed ID: 38349136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update of Gepants in the Treatment of Chronic Migraine.
    Cho S; Kim BK
    Curr Pain Headache Rep; 2023 Oct; 27(10):561-569. PubMed ID: 37656319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives.
    De Matteis E; Guglielmetti M; Ornello R; Spuntarelli V; Martelletti P; Sacco S
    Expert Rev Neurother; 2020 Jun; 20(6):627-641. PubMed ID: 32434430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real world considerations for newly approved CGRP receptor antagonists in migraine care.
    Scuteri D; Tonin P; Nicotera P; Bagetta G; Corasaniti MT
    Expert Rev Neurother; 2022 Mar; 22(3):221-230. PubMed ID: 35240905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.